Trials / Conditions / Refractory Mixed Phenotype Acute Leukemia

Refractory Mixed Phenotype Acute Leukemia

10 registered clinical trials studyying Refractory Mixed Phenotype Acute Leukemia — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leuke NCT05761171	Children's Oncology Group	Phase 2
Active Not Recruiting	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739	National Cancer Institute (NCI)	Phase 1
Withdrawn	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Tr NCT05320380	Children's Oncology Group	Phase 1 / Phase 2
Recruiting	Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms NCT04797767	University of Washington	Phase 1 / Phase 2
Recruiting	CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631	Fred Hutchinson Cancer Center	Phase 1
Recruiting	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Terminated	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refracto NCT02879695	National Cancer Institute (NCI)	Phase 1
Recruiting	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034	Fred Hutchinson Cancer Center	Phase 1 / Phase 2